Versameb AG, a Basel, Switzerland-based biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, closed a CHF 6m seed financing round.
The company intends to use the funds to progress its lead asset towards clinic by the end of 2021 and advance additional applications in therapeutic areas.
Led by Prof. Dr. Friedrich Metzger, Chief Executive Officer and Co-founder, Versameb is a preclinical-stage biopharmaceutical company focused of novel RNA-based therapeutics. Its proprietary VERSagile technology platform enables development of functional mRNA molecules in multiple disease areas with high unmet medical need including dermatology, oncology and myology.
The platform has been validated for these therapeutic targets and preclinical proof of principle has been established with its lead asset in animal models.
Versameb appointed Dr. Klaas P. Zuideveld as Chief Development Officer to advance its lead molecule into clinical development. Most recently, Dr. Zuideveld held the position of Vice President Pharmaceutical partnerships at Caris Life Sciences, where he was responsible for the company’s first companion diagnostic partnership and precision medicine led clinical trials. Prior to that, Dr. Zuideveld held leadership positions in drug development and consulted for Pharsight (acquired by Certara), F. Hoffmann-La Roche, Mosaic Biomedicals (acquired by Northern Biologics) and Therachon (acquired by Pfizer). He holds a Ph.D. from the University of Leiden, The Netherlands.